EUREKA = ELN registry

Study title

EUREKA = ELN registry for patients with chronic myeloid leukemia (CML) in chronic phase (CP) who have been treated with tyrosine kinase inhibitors for at least two years

Scientific title

European survey on the assessment of deep molecular response in chronic phase CML patients after at least two years of therapy with tyrosine kinase inhibitors (EUREKA)

Indication and most important inclusion criteria

This European registry enrolls male or female patients from 18 years of age with a diagnosis of BCR-ABL positive CML in chronic phase (CP).
The registry will be available to all CML patients after at least two years of treatment with one or more tyrosine kinase inhibitor(s) (TKIs) at any prescribed dose as per routine clinical practice for a minimum of 24 months at registry entry.

Short description of intervention

The EUREKA registry will collect and evaluate medical data and molecular results of the assessment of residual disease (deep molecular response, MR4.5) in patients with chronic myeloid leukemia (CML) in chronic phase (CP).

Deep molecular response is assessed routinely in the course of treatment of CML. Additional blood sampling will not be required.

Assessment results and biomaterials will be collected, stored and evaluated by specialized laboratories (certified MR4.5 labs). The data analysis is aiming to show the availability of deep molecular response assessment for all CML patients in Europe.

Type of study

Other trial = epidemiological registry

Current status

No longer recruiting

Study sponsor

European LeukemiaNet (ELN)

Scientific lead / contact

...

Principal investigator

Prof. Dr. med. Andreas Hochhaus
Universitätsklinikum Jena
Klinik Innere Medizin II
07740 Jena
Germany

Additional information

Description available at European Treatment and Outcome Study

Study centers / principal investigators

Participating countries:

Austria

Belgium

Bosnia-Herzegovina

Bulgaria

Croatia

Czech Republic

Denmark

France

Germany

Greece

Ireland

Italy

Lithuania

Norway

Poland

Portugal

Rumania

Slovenia

Spain

Switzerland

United Kingdom

 

 

OPTIC = Ponatinib in resistant chronic phase CML [Africa, Asia, Australia, Europe, North- and South America]

Study title

OPTIC = Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

Scientific title

OPTIC (Optimising Ponatinib Treatment In CML) - A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses (EudraCT 2014-001617-12, NCT02467270, AP24534-14-203)

Indication and most important inclusion criteria

This study includes patients who:
- have chronic myeloid leukemia in chronic phase (CP-CML) and are resistant to at least two prior tyrosine kinase inhibitors (TKI)
- are at least 18 years old, have an Eastern Co-Operative Group (ECOG) status of 0-2, have given written informed consent and comply with scheduled visits and study procedures
- have fully recovered from the acute effects of prior cancer therapy before initiation of study drug
- have adequate kidney, liver and pancreas function
- have a negative pregnancy test, use a highly effective form of contraception from randomization through at least 4 months after the end of treatment (for female and male patients who are fertile)

Additional criteria apply.

Short description of intervention

To characterize the efficacy of ponatinib administered in three starting doses (45mg, 30mg, and 15mg daily) in patients with CP-CML who are resistant to at least two TKIs, as measured by major cytogenetic response (MCyR) by 12 months.

Type of study

Therapy optimization trials

Current status

No longer recruiting

Study sponsor

Ariad Pharmaceuticals (acquired by Takeda)

Scientific lead / contact

Takeda Study Registration Call Center 866-835-2233
globaloncologymedinfo@takeda.com

Principal investigator

See site contact information

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Argentina

Buenos Aires, Argentina, 1221
Hospital Ramos Mejia (Site 826)
Contact: Claudio Merlo
Principal Investigator: Elena B Moiraghi, MD

Caba, Buenos Aires, C1114AAN
Fundaleu (Site 825)
Contact: Miguel Frau
Principal Investigator: Carolina Pavlovsky, M.D.

La Plata, Buenos Aires, B1900AXI
Hospital Italiano La Plata


Australia

New South Wales
St. Leonards, New South Wales, 2065
Royal North Shore Hospital (Site 941)
Contact: Vicki Katsioulas
Principal Investigator: Christopher K Arthur, MD

Adelaide, 5000
Royal Adelaide Hospital, Haematology Clinical Trials (Site 951)
Principal Investigator: Professor Timothy Peter Hughes


Canada

Ontario
Toronto, Ontario, M5G2M9
Princess Margaret Cancer Centre (Site 083)
Principal Investigator: Jeffrey Howard Lipton

Quebec
Montreal, Quebec, H3T IE2
Jewish General Hospital (Site 129)
Contact: Marie Pascale Guay
Principal Investigator: Sarit Assouline, MD

Saskatchewan
Regina, Saskatchewan, S4T 1A5
Pasqua Hospital (Site 227)
Principal Investigator: Haji Chalchal, MD


Chile

Providencia, Santiago, 7500922
Hospital del Salvador (Site 829)
Contact: Maria Gianna Capurro
Principal Investigator: Maria Soledad Undurraga Sutton, MD

Vina del Mar, Valparaiso, 254-0364
Centro de Investigaciones Clínicas Viña del Mar (Site 828)
Contact: Gina Castagneto
Principal Investigator: Christine Rojas Hopkins, MD


Czech Republic
Olomouc, 77520
Fakultni nemocnice Olomoue (Site 515)
Principal Investigator: prof. Karel Indrak, MD, PhD

Praha 2, 128 20
Ustav Hematologie a Krevni Transfuze Praha (UHKT) (Site 516)
Contact: Jana Vedrova
Principal Investigator: Hana Klamova


Denmark

Aarhus C, 8000
Haematologisk Afdeling, Arahus Universitehospital (Site 683)
Principal Investigator: Prof. Jesper Stentoft, M.D.


France

Angers Cedex 9, 44993 CHU Angers
Service Maladies du Sang (Site 685)
Principal Investigator: Dr. Martine Gardembas

Bordeaux, 33076
Centre de Lutte Contre le Cancer - Institut Bergonie (Site 772)
Principal Investigator: Dr. Gabriel Etienne

Lille, Nord, 59037 CEDEX Hopital Claude Huriez CHRU (Site 952)
Contact: Sylvie Brice
Principal Investigator: Valerie Coiteux, MD

Nantes Cedex, 44093
CHU Hotel-Dieu, Service d'Hematologie Clinique (Site 521)
Principal Investigator: Dr. Viviane Dubruille

Nice Cedex 3, 06202
Centre Hospitalier Universitaire de Nice Hopital l'Archet (Site 509)
Contact: Marie-Christine Rigualt
Principal Investigator: Laurence Legros

Poitiers, B.p. 577, 86021
CHRU de Poitiers, Department of Oncology-Hematology and Cell Therapy (Site 954)
Principal Investigator: Prof. Francois Guilhot

Toulouse Cedex 9, Midi-pyrenees, 31059
Institut Universitaire du Cancer de Toulouse Oncopole

Vandoeuvre-les-Nancy Cedex, 54511
University Teaching Hospital - CHU Brabois (Site 953)
Principal Investigator: Dr. Agnes-Paule Guerci-Bresler


Germany

Aachen, 52074
Universitätsklinikum Aachen, AOR (Site 513)
Contact: Sabrina Holst
Principal Investigator: Martina Crysandt, MD

Berlin, 13353
Universitätsmedizin Berlin - Charité (CVK) (Site 701)
Contact: Peggy Grill
Principal Investigator: Philipp Le Coutre, MD

Essen, 45147
Essen University Hospital (Site 686)
Contact: Ilona Vester
Principal Investigator: Jürgen Novotny, MD

Hamburg, 20246
University Cancer Center Hamburg (Site 524)
Hubertus Wald Tumorzentrum
Contact: Juliane Granzow
Principal Investigator: Philippe Schafhausen, MD

Jena, 07747
Universitätsklinikum Jena (Site 946)
Contact: Denise Mathes
Principal Investigator: Andreas Hochhaus, PhD, MD

Mannheim, 68169
University of Heidelberg (Site 947)
Contact: Regina Pleil-Losch
Principal Investigator: Susanne Saussele, MD

Rostock, 18057
Universitatsmedizin Rostock

Ulm, 89081
University Hospital of Ulm (Site 694)
Contact: Beate Böltau
Principal Investigator: Frank Stegelmann, MD


Hong Kong

Hong Kong, 852
Queen Mary Hospital


Italy

Catania, 95124
University Hospital Policlinico (Site 530)
Contact: Giovanna Pappalardo
Principal Investigator: Francesco Di Raimondo, MD

Genova, 16132
Azienda Ospedaliera Universitaria San Martino
V.O. Clinica Ematologica (Site 528)
Contact: Maria Attilia Grassi
Principal Investigator: Marco Gobbi

Monza, 20090
ASST San Gerardo Hospital (Site 355)
Contact: Dario Cerri
Principal Investigator: Carlo Gambacorti-Passerini, MD

Pesaro, Pesaro e Urbino, 61100
A.O. Ospedali Riuniti Marche Nord (Site 689)
Contact: Maurizio Nardelli
Principal Investigator: Giuseppe Visani, MD

Pescara, 65124
Pescara Civil Hospital (Site 688)
Contact: Giuseppina Di Florio
Principal Investigator: Paolo Di Bartolomeo, MD

Roma, 00161
University La Spienza (Site 511)
Contact: Enrica Arduini
Principal Investigator: Giuliana Alimena

Verona, 37134
Ospedale Borgo Roma - Verona (Site 687)
Contact: Giorgia Barbiero
Principal Investigator: Massimiliano Bonifacio, MD


Korea, Republic of

Seoul, Korea, Republic of, 137-701
The Catholic University of Korea Seoul
St. Mary's Hospital (Site 938)
Principal Investigator: Dong-Wook Kim, M.D., PhD


Poland

Gdansk, Pomorskie, Poland, 80-952
Uniwersyteckie Centrum Kliniczne

Krakow, 30-510
Malopolskie Medical Center (Site 546)
Contact: Marta Kowalowka
Principal Investigator: Tomasz Sacha, MD

Łódź, Poland, 93-510
Klinika Hematologii Uniwersytetu Medycznego w Łodzi (Site 550)
Contact: Magdalena Przybysz
Principal Investigator: Tadeusz Robak, MD

Warszawa, Poland, 02-776
Klinika Hematologii (Site 691)
Contact: Urszula Szustkiewicz
Principal Investigator: Krzysztof Warzocha, MD

Wrocław, Poland, 50-369
Independent Public Clinical Hospital No. 1 in Wroclaw (Site 547)
Contact: Mariusz Grajcar
Principal Investigator: Ewa Medras, MD


Portugal

Lisboa, 1090-023
Instituto Portugues de Oncologia de Lisboa (Site 545)
Contact: Ana Inacio
Principal Investigator: Antonio M Almeida, MD/PhD

Porto, 4200-319
Centro Hospitalar de S. João (Site 559)
Contact: Raquel Ribeiro
Principal Investigator: Manuel S Simões

Russian Federation

Chelyabinsk, 454076
Chelyabinsk Regional Clinical Hospital

Kemerovo, 650066
Kemerovo Regional Clinical Hospital (Site 455)
Contact: Ludmila Chervova
Principal Investigator: Marina Kosinova, MD

Moscow, 111123
GBUZ Moscow Clinical Scientific Center (Site 453)
Contact: Galina Dudina
Principal Investigator: Mikhail Y Byakhov, MD

Moscow, 125167
Russian Academy of Medical Science
Haematological Scientific Center (Site 452)
Contact: Nemchenko Irina, MD
Principal Investigator: Anna Turkina, MD

Rostov-na-Donu, Rostov, 344022
Rostov State Medical University

Saint Petersburg, 191024
FGU Russian Scientific Research Institute of Hematology and Transfusiology

Saint-Petersburg, 197341
Federal State Budgetary Institution V. A. Almazov
Federal North-West Medical (Site 454)
Contact: Irina Shakhomirova
Principal Investigator: Elza Lomaia, MD

Samara, 443099
Samara State Medical University

Saratov, Russian Federation, 355018
Saratov State Medical University


Singapore

Outram Road, Singapore, 169608
Singapore General Hospital (Site 939)
Principal Investigator: Dr. Charles Chuah Thuan Heng


Spain

Barcelona, Cataluna, 08036
Hospital Clinic, Service de Hematologia (Site 963)
Principal Investigator: Francisco Cervantes

Las Palmas de Gran Canaria, Islas Canarias, 35010
Hospital Universitario de Gran Canaria Dr Negrin (Site 692)
Contact: Mireya A Lopez
Principal Investigator: Maria Teresa Gomez Casares, MD

Madrid, 28006
Hospital Universitario de la Princesa
Hematology Service, 2a Planta (Site 555)
Principal Investigator: Juan Luis Steegmann Olmedillas

Madrid, 28034
Hospital Universitario Ramon y Cajal (Site 538)
Principal Investigator: Valentin Garcia Gutierrez
Hospital Clinico Universitario de Valencia (Site 964)

Malaga, Andalucia, 29010
Hospital Regional Universitario Carlos Haya (Site 698)
Principal Investigator: Antonio Jimenez Velasco

Valencia, Spain, 46010
Hospital Clinico Universitario de Valencia (Site 964)
Principal Investigator: Juan Carlos Hernandez Boluda


Sweden

Uppsala, SE-751 85
University Hospital Uppsala (Site 945)
Contact: Aime Mukenyuzi
Principal Investigator: Ulla Olsson-Stromberg, M.D., Ph.D.


Switzerland

Zurich, 8091
University Hospital Zurich (Site 562)
Contact: Isabell Pieper-Scholz
Principal Investigator: Stefan Balabanov, MD


Taiwan

Taipei, 100
National Taiwan University Hospital (Site 979)
Principal Investigator: Jih-Luh Tang, M.D., PhD.


United Kingdom

Glasgow, G12 0YN
NHS Greater Glasgow & Clyde
The Beatson West of Scotland Cancer Centre (Site 797)
Principal Investigator: Professor Tessa Holyoake

Liverpool, L7 8XP
The Royal Liverpool University Hospital (Site 969)
Principal Investigator: Professor Richard Clark

London, SE5 9RS
King's College Hospital NHS Foundation Trust (Site 693)
Principal Investigator: Dr. Hugues de Lavallade

London, W12 0NN
Imperial College Healthcare NHS Trust (Site 967)
Contact: Regina Storch
Principal Investigator: Jane F Apperley, MD

Nottingham, NG5 1PB
The Centre for Clinical Haematology
Notthingham University Hospitals NHS Trust (Site 968)
ontact: Maria Scott
Principal Investigator: Jennifer Byrne

Oxford, OX3 7LE
Churchill Hospital


United States

Georgia
Atlanta, Georgia, 30322
Emory University Hospital Winship Cancer Institute (Site 058)
Principal Investigator: Vamsi Kota, MD

Indiana
Indianapolis, Indiana, 46237
Indiana Blood and Marrow Transplantation Clinic (Site 138)
Principal Investigator: Luke Akard, MD

Maryland
Baltimore, Maryland, 21201
University of Maryland Medical Center (Site 040)
Principal Investigator: Maria Baer, MD

Michigan
Ann Arbor, Michigan, 48109
University of Michigan Health System (Site 011)
Principal Investigator: Moshe Talpaz, MD

Detroit, Michigan, 48201
Karmanos Cancer Institute (Site 034)
Principal Investigator: Charles Schiffer, MD

Minnesota
Minneapolis, Minnesota, 55455
University of Minnesota Medical School

Nebraska
Omaha, Nebraska, 68198-7680
University of Nebraska Medical Center (Site 235)
Principal Investigator: Lori Maness-Harris, MD

New Jersey
Hackensack, New Jersey, 07601
Hackensack University Medical Center (Site 128)
Principal Investigator: James McCloskey II

New York
New York, New York, 10065
Memorial Sloan Kettering Cancer Center (Site 078)
Contact: Gerald O'Neill
Principal Investigator: Michael Mauro, MD

New York, New York, 10065
Weill Medical College of Cornell University and New York Presbyterian Hospital (Site 006)
Contact: Rachael Alettie
Principal Investigator: Ellen Ritchie, MD

North Carolina
Durham, North Carolina, 27710
Duke University Medical Center (Site 003)
Contact: Cheryl M Maxey
Principal Investigator: Joseph Moore, MD

Ohio
Cleveland, Ohio, 44195
Cleveland Clinic Foundation (Site 004)
Principal Investigator: Dr. Sudipto Mukherjee

Oregon
Portland, Oregon, 97239
Oregon Health & Science University (Site 048)
Contact: Jeanne Liming
Principal Investigator: Michael Heinrich

Pennsylvania
Philadelphia, Pennsylvania, 19104
Abramson Cancer Center (Site 013)
Principal Investigator: Selena Luger, MD

Texas
Houston, Texas, 77030
MD Anderson Cancer Center (Site 005)
Principal Investigator: Jorge E. Cortes, MD

Utah
Salt Lake City, Utah, 84112
Huntsman Cancer Institute (Site 043)
Principal Investigator: Michael Deiningeri, MD

 

 

Pioglitazone and TKI [USA]

Study title

Pioglitazone and Tyrosine Kinase Inhibitor in Patients with Relapsed CML [USA]

Scientific title

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (NCT 02730195).

Indication and most important inclusion criteria

This study includes patients 16 years and older with chronic myeloid leukemia (CML) in any phase. Patients are eligible for inclusion if they have lost major molecular response (MMR) after a first tyrosine kinase inhibitor (TKI) stop trial.

Short description of intervention

This is a study to find out if pioglitazone hydrochloride enhances the activity of tyrosine kinase inhibitor therapy in patients with CML that has come back after a first TKI discontinuation. The success of the combination is measured by the rate of successful second discontinuation of TKI. Pioglitazone hydrochloride is a drug approved in the USA to treat diabetes and has been shown in laboratory studies to increase CML stem cell death when given together with TKI therapy.

Patients receive pioglitazone hydrochloride by mouth once daily on days 1-28. Patients also start or continue the same TKI therapy as before stopping. Courses repeat every 28 days for 6 months unless the disease progresses or unacceptable side effects occur.

Type of study

Therapy optimization trial

Current status

recruiting

Study sponsor

Emory University, Georgia, USA

Scientific lead / contact

Shannon Gleason
shannon.gleason@emory.edu

Principal investigator

Vamsi Kota, MD

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Emory University/Winship Cancer Institute
Vamsi Kota, MD
Georgia, 30322
United States

 

 

MSIT = Malaysia Stop Tyrosine Kinase Inhibitor Trial [Malaysia]

Study title

MSIT = Malaysia Stop Tyrosine Kinase Inhibitor Trial [Malaysia]

Scientific title

A Randomized Control Trial Comparing Peginterferon-α-2a Versus Observation After Stopping Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia With Deep Molecular Response for at Least Two Years (ClinicalTrials.gov NCT02381379)

Indication and most important inclusion criteria

To be considered for inclusion in this study patients must be 18 years or older and have been diagnosed with chronic phase (CP) chronic myeloid leukemai (CML). They have been treated with ongoing tyrosine kinase inhibitors (TKI) at any dose for at least 3 years.
Patients have achieved stable deep molecular response (MR4.5) on International Scale (IS) for at least 2 years. The last deep MR result must have been from within 3 months of enrollment.

Short description of intervention

This study compares two groups of CML patients in chronic phase with deep molecular response for at least 2 years. After stopping tyrosine kinase inhibitors, one group will use peginterferon-α-2a starting at 180µg weekly for one year whereas the other group will not use any active medication that might affect CML.
The study will compare the two groups with regard to relapse rate, time to re-attain deep molecular response after restarting TKIs in patients who relapse and time to regain deep molecular response after relapse after restarting whatever treatment.

Type of study

Treatment discontinuation trial
in a single country

Current status

Recruiting

Study sponsor

Ministry of Health, Malaysia

Scientific lead / contact

Jew Win Kuan, MRCP (UK)
Kian Meng Chang, FRCP, London

Principal investigator

Kian Meng Chang, FRCP, London
Ampang Hospital, Malaysia

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Malaysia

Sultanah Aminah Hospital
Johor Bahru, Johor, Malaysia, 80100

Sultanah Bahiyah Hospital
Alor Setar, Kedah, Malaysia, 05460

Queen Elizabeth Hospital
Kota Kinabalu, Sabah, Malaysia

Sarawak General Hospital
Kuching, Sarawak, Malaysia, 93586

Miri Hospital
Miri Sarawak, Malaysia, 98000

Sibu Hospital
Sibu, Sarawak, Malaysia, 96000

Ampang Hospital
Ampang, Selangor, Malaysia, 68000

Malacca General Hospital
Melaka, Melaka, Malaysia, 75400 

 

 

ENESTPath Patient's Voice Italian Substudy [Italy]

ENESTPath Patient's Voice Italian Substudy [Italy]

ENESTPath Patient's Voice Italian Substudy

Scientific title

CML patient's voice: A pilot sub-study exploring the emotional experience of patients during CAMN107AIC05 Study - Italian substudy of ENESTPath (clinicaltrials.gov NCT01743989, EudraCT 2012-005124-15)

Indication and most important inclusion criteria

Patients in consolidation study phase of ENESTPath who will perform visit 6 at the time of sub-study activation

Short description of intervention

Patients from Italian centres participating in ENESTPath will undergo specific Quality of Life and psychological assessments during the consolidation and treatment-free remission phase.

The following tools will be used:

  • Patient Diary
  • EORTC QLQW-C30: a questionnaire to assess the quality of life of cancer patients
  • EORTC-CML: a questionnaire to assess the quality of life of CML patients
  • Sixteen Personality Factor Questionnaire (16PF): a self-report personality test;
  • Symptom Checklist 90 (SCL.90-R): a self reported questionnaire

Type of study

5. Treatment discontinuation trials
In a single country

Current status

Active, not recruiting

Study sponsor

Novartis

Scientific lead / contact

Claudia Galimberti Novartis Farma S.p.A.

Principal investigator

Luca Dezzani Novartis Farma S.p.A.

Additional information

...

Study centers / principal investigators

Italian centers participating in ENESTPath

 

 

 

NAUT (CAMN107ADE22T) = Efficacy of nilotinib in inducing persistence of molecular remission after second or third TKI stop [Europe]

Study title

Efficacy of nilotinib in inducing persistence of molecular remission after second or third TKI stop

Scientific title

Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping tyrosine kinase inhibitors a second or third time (ClinicalTrials.gov NCT02917720; EudraCT no. 2015-004998-33)

Indication and most important inclusion criteria

This study includes patients from 18 years of age with chronic myeloid leukemia (CML) who have had a molecular relapse after a prior first or second attempt to stop therapy with a tyrosine kinase inhibitor (TKI) therapy and who have been treated for at least one year with any TKI after the first stop.

Short description of intervention

Patients will be treated with nilotinib 600 mg/day for at least two years. Patients who achieve deep molecular remission (MR4.5 or better) at the end of treatment can attempt stopping TKI treatment.

The main objective of the study is to assess whether more patients maintain at least major molecular remission at 12 and 36 months after stopping TKI therapy.

Type of study

Treatment discontinuation trial

Current status

recruiting

Study sponsor

University of Heidelberg, Germany, with financial support from Novartis GmbH

Scientific lead / contact

Prof. Dr. Susanne Saußele
MCC-Studienzentrale, III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
68167 Mannheim

Principal investigator

Prof. Dr. Susanne Saußele
MCC-Studienzentrale, III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
68167 Mannheim

Additional information

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

Germany

Aachen
Universitätsklinikum der RWTH Aachen
Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation
Prof. Dr. med. Tim Henrik Brümmendorf
Pauwelsstr. 30
52074 Aachen

Bayreuth
Klinikum Bayreuth GmbH
Medizinische Klinik IV
PD Dr. med. Alexander Kiani
Preuschwitzer Str. 101
95445 Bayreuth

Chemnitz
Klinikum Chemnitz gGmbH
Klinik für innere Medizin III
Dr. med. Mathias Hänel
Flemmingstr. 2
09113 Chemnitz

Esslingen
Onkologische Schwerpunktpraxis
Dr. med. Robert Eckert
Berliner Str. 4
73728 Esslingen

Freiburg
Universitätsklinikum Freiburg
Innere Medizin I
Prof. Dr. Cornelius Waller
Hugstetter Str. 55
79108 Freiburg

Halle (Saale)
Universitätsklinikum Halle
Universitätsklinik und Poliklinik für Innere Medizin IV
PD Dr. med. Haifa Kathrin Al-Ali
Ernst-Grube-Str. 40
06120 Halle (Saale)

Hannover
Medizinische Hochschule Hannover
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation
PD Dr. med. Christian Könecke
Carl-Neuberg-Str. 1
30625 Hannover

Heilbronn
Schwerpunktpraxis Onkologie
Dr. med. Jolanta Dengler
Allee 40
74072 Heilbronn

Mannheim
MCC-Studienzentrale, III. Med. Klinik
Medizinische Fakultät Mannheim der Universität Heidelberg
Prof. Dr. Susanne Saußele
68167 Mannheim

Marburg
Universitätsklinikum Gießen und Marburg,
Standort Marburg
Klinik für Hämatologie, Onkologie und Immunologi
Prof. Dr. med. Andreas Burchert
35043 Marburg

München
Klinikum rechts der Isar
Klinik und Poliklinik für innere Medizin III
Dr. med. Peter Herhaus
Ismaninger Str. 22
81675 München

Mutlangen
Klinikum Ostalb, Stauferklinikum Schwäbisch Gmünd
Zentrum für Innere Medizin
Prof. Dr. Holger Hebart
Wetzgauer Str. 85
73557 Mutlangen

Rostock
Universitätsmedizin Rostock
ZIM III - Hämatologie, Onkologie, Palliativmedizin
Prof. Dr. med. Christian Junghanß
Ernst-Heydemann-Straße 6
18057 Rostock

Villingen Schwenningen
Schwarzwald-Baar Klinikum
Klinik für Innere Medizin II
Prof. Dr. med. Paul Graf La Rosée
Klinikstraße 11
78052 Villingen-Schwenningen


The Netherlands

VU University Medical Center Amsterdam
Dr. Jeroen Janssen
1081 HV Amsterdam

 

 

Subcategories

Please donate!

Please donate!

LogIn

EU e-Privacy Directive